Blog
RSS FeedPosted by Michael Wonder on 20 Jun 2024
The value of the quality adjusted life years
19 June 2024 - Concerns about quality-adjusted life years (QALYs) being discriminatory have reached a fever pitch in the US, culminating ...
Posted by Michael Wonder on 20 Jun 2024
What good are whizzy new drugs if the world can’t afford them?
14 June 2024 - Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson. ...
Posted by Michael Wonder on 05 Jun 2024
ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access
5 June 2024 - This year’s analysis will include the top ten commercial formularies by covered lives, and include drugs ...
Posted by Michael Wonder on 30 May 2024
ICER publishes evidence report on treatment for chronic obstructive pulmonary disease
30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds ...
Posted by Michael Wonder on 14 May 2024
ICER publishes evidence report on treatment for post-traumatic stress disorder
14 May 2024 - There are substantial uncertainties around the clinical trial results; given the inability to assess net benefit, ...
Posted by Michael Wonder on 09 May 2024
ICER releases draft evidence report on treatment for anaemia in myelodysplastic syndrome
9 May 2024 - Public comment period now open until 10 June 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 02 May 2024
ICER to assess treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
2 May 2024 - Report will be subject of New England CEPAC meeting in November 2024; draft scoping document open ...
Posted by Michael Wonder on 23 Apr 2024
ICER and NEWDIGS release white paper analysing the challenges and potential policy options for paying for gene therapies
23 April 2024 - Paper outlines policy reforms and market actions to support innovation and access while managing uncertainty, affordability, ...
Posted by Michael Wonder on 10 Apr 2024
ICER releases draft evidence report on treatment for chronic obstructive pulmonary disease
10 April 2024 - Public comment period now open until 7 May 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Apr 2024
ICER publishes 2024 research protocol for assessing unsupported price increases on prescription drugs
9 April 2024 - Input period now open until 13 May 2024. ...
Posted by Michael Wonder on 26 Mar 2024
ICER releases draft evidence report on treatment for post-traumatic stress disorder
26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 14 Mar 2024
ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria
13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 11 Mar 2024
ICER publishes final evidence report on treatment for schizophrenia
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
Posted by Michael Wonder on 08 Mar 2024
ICER to assess treatments for transthyretin amyloidosis cardiomyopathy
7 March 2024 - Report will be subject of Midwest CEPAC meeting in September 2024; draft scoping document open to ...
Posted by Michael Wonder on 01 Feb 2024
ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria
1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...